Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
From the Times:
Mike Abbott used to be a north London copper who arrested people for smoking marijuana, but at 3pm on a warm Tuesday afternoon he takes me to buy cannabis in Camden Town. “I know it’s legal, but it still feels a bit odd,” he says as he examines the cannabis oils in the LDN CBD store, before recommending I buy the 5% strength bottle. At £35 for just 10ml, it had better be good.
Abbott is not just there to help me. He is checking out the competition. He has had something of a career change after leaving the Metropolitan police, and is now in the marijuana business himself. He joined a Manhattan-based medical cannabis start-up called Columbia Care and has risen to be chairman. The firm makes and sells cannabis-based medicines, which, under doctors’ orders, can be used to treat conditions such as epilepsy. Separately, it makes over-the-counter wellness products — oils and creams — that users say help with everything from anxiety to irritable bowel syndrome.
It’s tempting to dismiss men like Abbott as potheads with a dream — but that could be a big mistake. Marijuana-based prescription drugs and wellness products are growing like weeds. About one in 10 British adults have tried them, according to surveys conducted this summer by Dynata and YouGov. Some analysts reckon the products are more popular than vitamin C supplements. The consultancy Prohibition Partners claims the sector as a whole could be worth up to £100bn in Europe within the next 10 years. That would put it on a par with the brewing industry.
Britain is emerging as a cannabis research and development hub, thanks to its strong medical research and pharmaceutical sectors. One Cambridge-based firm, GW Pharmaceuticals, is the world leader in licensed prescription cannabis medicines. It has created two drugs that have been approved for use to treat multiple sclerosis and two severe forms of childhood epilepsy, earning it a market capitalisation of more than £3.5bn. Chris Tovey, its chief operating officer, describes the medical marijuana sector as “amazingly exciting for the UK”.
So what exactly are the new marijuana products that are generating such high hopes? First, it’s perhaps best to say what they are not. They are not about smoking weed. Indeed, most people in the medical and wellness cannabis business are at pains to distance themselves from bongs and Rizlas because most argue that the superstrong “skunk” sold illegally by many dealers contains dangerously high levels of delta-9-tetrahydrocannabinol (THC). That’s the psychoactive compound in the cannabis plant that gets you high, but which can also lead to mental health problems such as anxiety and paranoia, and may increase the risk of schizophrenia and bipolar disorders. For these reasons, cannabis remains a class B drug in Britain, possession of which can lead to a jail term of up to five years.
Mana,
10 working days ago the company released the RNS
"It confirms that the Company is in discussion with multiple potential licensees in Japan and Asia, including but not limited to its NXP002 programme. "
If they are in negotiations they are sensitive and take time . Simples
I think watching every trade doesn't help
Good useful research by Mars1 over the weekend.
From this report the liver fibrosis market is already at $12.2 billion (2018) forecast to reach $22 Billion by 2025 so much bigger than original estimates due to changes in diet and lifestyle.
Also biggest market is North America.
Also, existing treatments won't heal, just stabilise.
Great opportunity here
https://www.medgadget.com/2019/08/liver-fibrosis-drug-market-size-share-analysis-opportunities-and-forecast-to-2019-2025.html
I note Dan specifically states about the negotiation with potential licensees in Japan and Asia but does not include other hugely potential markets (revenue wise) such as US and Europe. Why wouldn't they be in discussions with these also?
Actually quite positive mention this time (probably because he's bought some).
NFX mentioned about 17 mins 15 seconds
https://audioboom.com/posts/7412636-the-weekend-podcast?utm_campaign=detailpage&utm_content=retweet&utm_medium=social&utm_source=twitter
Investor,
It's an impressive list of conditions that it will or could be able to treat. I see Alzheimer's disease is in there and with no worldwide cure available, that would be huge! Just IPF alone is huge. That's why the figure of £200 million could well be credible, when testing is passed.
Anyone know if Alan Miller the guy exercising his warrants is the star ex fund manager who made millions with New Star and Gartmore Jupiter?
If he still holds the ones from the loan conversion in May he now has > 17.4m shares and over 3%. He had 60 months from May to exercise so interesting timing.
Hi Bgasensio,
Thanks for that info and that makes perfect sense now. I'd read of the couple of Patents Nuformix had been granted for Tranilast but didn't realise that Kissei was the Pharma. It's one hell of a drug...or it will be with Co-crystals going by the list of conditions it can be used for:
The links for the Tranilast US Patents filed for those that haven't seen:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=4&f=G&l=50&co1=AND&d=PTXT&s1=nuformix&OS=nuformix&RS=nuformix
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=2&f=G&l=50&co1=AND&d=PTXT&s1=nuformix&OS=nuformix&RS=nuformix
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=nuformix&OS=nuformix&RS=nuformix
Agreed Np about potential.
I'm just working on the assumption that CPI are wanting to unload as they had done previously. Dan has no jurisdiction over CPI (maybe some loose agreement) so it's possible and my supposition that they took the opportunity to offload more. There were some meaty sells in there too but as you say may also be PI's who don't get the story.
I wonder if we might see a TR1 this week from CPI as undoubtedly they will have been unloading quite a bit of their holding I would have thought. There were 44m traded yesterday so I would suspect that they would have unloaded several million. It would be good to have them cleared as then I would see a greater squeeze on the sp. Whilst there is a seller in the background this will keep a lid on the rise in the short term IMV
Also, in the company RNS response yesterday:
"It confirms that the Company is in discussion with multiple potential licensees in Japan and Asia, including but not limited to its NXP002 programme. "
This little teaser from NFX could also mean assisting with co-crystal solutions for other drugs in their portfolio that have failed due to efficacy.
No doubt all will be revealed in the next few days or weeks
Having re-read this article there is a part of this I originally missed:
"Nuformix uses co-crystal technology to re-engineer drugs. Market gossip suggests that Kissei is in talks to license Nuformix’s lead fibrosis treatment alongside its unique oral delivery system.
The proprietary delivery mechanism resolves a number of efficacy problems that have plagued Kissei for years, they claim. The partnership could enable Kissei to treat other conditions."
Does anyone else think that this last paragraph may also relate to other Kissei drugs that they have developed but struggled with efficacy and side effects that NFX maybe assisting with to improve with co-crystals?
Just a thought
Dave
Agreed cfhmetal. They need the money to be able to develop the pipeline further. That is their model and to date it's worked well. We don't know how the Chinese situation is is now impacting developments so need clarity on what's happening and how it's being addressed.